Background
==========

Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder, that is characterized by frequent abdominal pain/discomfort, abdominal bloating/distension and an altered stool pattern \[[@B1]-[@B4]\]. Post-infectious IBS (PI-IBS) is a subset of IBS, and is characterized as a sudden onset of IBS symptoms following gastroenteritis in individuals who have had no gastrointestinal complaints \[[@B5]\]. The proportion of patients developing IBS following gastroenteritis varied between studies, from 3.7% to 36% \[[@B5]\]. Patients with IBS are more common in patients presenting with bacterial gastroenteritis to primary care physician than community controls \[[@B6]\]. This may indicate that IBS patients are predisposed to bacterial gastroenteritis, or that they tend to seek their doctor for bowel symptoms more often than the background population. Human infections caused by *Campylobacter jejuni* are a leading cause of food-borne enteritis, the bacteria usually being transmitted by the ingestion of undercooked poultry, or contact with farm animals. This infection leads to PI-IBS in 9-13% of cases \[[@B5],[@B7]-[@B9]\]. The symptoms of PI-IBS meet the Rome criteria for IBS with diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M) \[[@B10]-[@B12]\].

In IBS, there appears to be a general depletion of gastrointestinal endocrine cells, and especially serotonin and PYY cells \[[@B13],[@B14]\], whereas in PI-IBS there is an increase in the density of these cells, especially serotonin and PYY cells \[[@B1],[@B5],[@B11]\]. Furthermore, a low-grade inflammation has been reported in PI-IBS, which is manifested by increased intraepithelial lymphocytes and an infiltration of mast cells in the lamina propria of the large intestine \[[@B5],[@B15]-[@B17]\]. It has been suggested that the alterations in the population of gastrointestinal endocrine cells and the low-grade inflammation play a role in the pathogeneses of both sporadic and PI-IBS \[[@B1],[@B5],[@B13]\].

Case presentation
=================

A 20-year-old female was investigated for recurrent abdominal pain, abdominal distension, constipation and nausea. She had a bowel movement every 7--10 days, with straining at defecation and hard or lumpy stools. She was non-smoker and was not currently taking any medications. This patient had suffered from these symptoms since her childhood. Her mother had similar symptoms and had a diagnosis of IBS. Her symptoms affected her schoolwork and isolated her socially; she has been hospitalized on many occasions. The patient submitted to a complete physical examination and was investigated by means of blood (full blood count, electrolytes, calcium, and inflammatory markers), liver, and thyroid function tests. She also underwent gastroscopy with duodenal biopsy sampling and colonoscopy with segmental biopsy sampling. The findings of all these examinations and tests were normal. The patient fulfilled Rome III criteria and was thus given the diagnosis of IBS with constipation (IBS-C). She was asked to complete the three following questionnaires (Table [1](#T1){ref-type="table"}): Birmingham IBS Symptom scores, Short-Form Nepean Dyspepsia Index (SF-NDI) measuring the reduction in quality of life and Irritable Bowel Syndrome quality of life (IBS-QOL) \[[@B18]-[@B20]\]. She was then submitted to a non-pharmacological treatment program at our clinic, which includes provision of information and reassurance, dietary guidance, regular exercise and regular intake of probiotics \[[@B21]\]. Her symptoms subsequently reduced and her quality of life improved.

###### 

**Symptoms and quality of life in the patient before, during and after*Campylobacter*infection**

  **Questionnaire**    **Before infection**   **During infection**   **After infection**            
  ------------------- ---------------------- ---------------------- --------------------- ---- ---- ----
  Birmingham                                                                                          
  Total score                   30                     35                    26            18   29   4
  Pain                          6                      15                     4            3    6    2
  Diarrhoea                     4                      20                    12            8    5    0
  Constipation                  20                     0                     10            7    20   2
  SF-NDI                        29                     48                    20            17   28   13
  IBS-QOL^a^                    61                     50                    84            86   60   94

Six months after infection, the patient was treated with 2 mg prucalopride daily.

Birmingham, Birmingham Irritable Bowel Syndrome Symptom Questionnaire; SF-NDI, Short-Form Nepean Dyspepsia Index; IBS-QOL, Irritable Bowel Syndrome Quality Of Life Questionnaire.

^a^Percentage of the total score.

Seven months later, the patient was referred to the causal department because of a 3-day history of bloody diarrhoea occurring between 10 to 15 times daily, extreme fatigue and dehydration. She did not have a fever and with the exception of C-reactive protein (CRP), which was 17 mg/l (normal range 0--10 mg/l), her blood tests were normal. Colonoscopy revealed severe colonic inflammation with erythema, oedema, friable mucosae, haemorrhagic spots and ulcers. Biopsy samples taken during colonoscopy revealed preserved crypt architecture. However, a focal increase in the density of immune cells in the lamina propria and focal cryptitis and crypt abscesses were observed. Stool culture was positive for *Campylobacter jujeni.* The patient was treated with 400-mg metronidazole, twice daily for 2 weeks.

The findings of a physical examination and blood tests performed at follow-up visits at the outpatient clinic 2, 4, 6 and 12 months after *Campylobacter* infection were normal. Colonoscopy at 2 and 4 months visits revealed a normal endoscopic appearance. Moreover, the patient's general condition was improved. Her symptom pattern had changed and she experienced an improvement in her quality of life (Table [1](#T1){ref-type="table"}). Reassessment of her symptoms according to Rome III criteria put the patient into the IBS-M subtype. Six months following the *Campylobacter* infection, the patient suffered from abdominal pain, abdominal distension, constipation and nausea in the same degree as before the infection. She was treated with 2 mg prucalopride daily. Six months later, the patient's symptom was reduced and her quality of life improved (Table [1](#T1){ref-type="table"}).

Colonic and rectal biopsy samples obtained during colonoscopy before, during, and 2 and 4 months after *Campylobacter* infection were fixed overnight in 4% buffered paraformaldehyde, embedded in paraffin, and cut into 5-μm sections. The sections were immunostained with the avidin-biotin --complex (ABC) method using Vectastain ABC-kit and 3,3′-diaminobenzidine (DAB) peroxidase Substrate Kit (Vector laboratories). The sections were incubated with the primary antiserum/antibody at room temperature for 2 h. The sections were then washed in PBS buffer and incubated with biotinylated swine anti-mouse (in the case of monoclonal antibodies) or anti-rabbit IgG (in the case of polyclonal antibodies) diluted 1:200 for 30 min at room temperature. After washing the slides in PBS buffer, the sections were incubated for 30 min with avidin-biotin-peroxidase complex diluted 1:100, and then immersed in 3,3′-diaminobenzidine (DAB) peroxidase substrate, followed by counterstaining in hematoxylin. The following primary antisera/antibodies were used: monoclonal mouse anti-N-terminal of purified Chromogranin A (Dako, code no. M869), monoclonal mouse anti-serotonin (Dako, code no. 5HT-209), polyclonal anti-porcine peptide PYY (Alpha-Dagnostica, code PYY 11A), polyclonal rabbit anti-synthetic-human PP (Diagnostic Biosystems, code no. \#114), polyclonal rabbit anti-porcine glicentin/glucagon (Acris Antibodies, code BP508), polyclonal rabbit anti-synthetic-human somatostatin (Dako, code no. A566); monoclonal mouse anti-human CD45 (Dako, code no. M0701), monoclonal mouse anti-human CD47 (Dako, code no. I5647), monoclonal mouse anti-human CD68 (Dako, code no. M0814) and monoclonal mouse anti-human mast cell tryptase (Dako, code no. M7052). CD45 is considered as a leucocyte common antigen and is expressed exclusively on cells of the hematopoietic system and their progenitors. CD57 is expressed by subsets of NK cells and CD8+ lymphocytes, and by a small percentage of CD4+/CD45R0+ T lymphocytes. CD68 labels human monocytes, macrophages and myeloid cells. Human mast cell tryptase comprise a family of trypsin-like neutral serine proteases that are predominantly expressed in mast cells. The total leucocytes, lymphocytes and mast cells, as well as chromogranin A, serotonin, peptide YY (PYY), and somatostatin cells. The densities of these cells were quantified by computerized image analysis using Olympus cellSens imaging software (version 1.7) on a computer linked to an Olympus microscope type BX 43 with an Olympus camera (DP 26). A ×40 objective was used, for which each frame (field) on the monitor represented a tissue area of 0.14 mm^2^ of the tissue. The number intraepithelial leucocytes cells and the endocrine cells as well as the area of the epithelial cells were measured in each field. The number of leucocytes, lymphocytes, and mast cells in lamina propria were counted per microscopic field. All measurements were done in 10 randomly chosen fields for each individual.

The densities of both intraepithelial and lamina propria leucocytes and lymphocytes were increased in both the colon and rectum at 2 and 4 months after the *Campylobacter* infection (Figure [1](#F1){ref-type="fig"}), as were the number of mast cells in the lamina propria in both the colon and rectum (Figure [2](#F2){ref-type="fig"}, Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). The total number of endocrine cells in the colon and rectum prior to *Campylobacter* infection (as detected by chromogranin A staining) was low, but within the normal limits (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). This is in agreement with previously published results in IBS-C patients \[[@B22],[@B23]\]. Although chromogranin A is used as a common marker for peptide hormone containing cells, chromogranin A immunoreactivity varies between gastrointestinal segments and even within population of the same endocrine cell type \[[@B24]\]. It has been found that chromogranin A- immunoreactive cells are not representative of the entire population of endocrine cells and that they are the least numerous of all of the endocrine cells combined \[[@B25]\]. The densities of serotonin and PYY cells had increased in both the colon and rectum during, 2 and 4 months post-infection (Figure [3](#F3){ref-type="fig"}). However, somatostatin cell density in the rectum was reduced in the rectum during and after *Campylobacter* infection.

![**Leucocytes in the patient before*Campylobacter*infection (A), during (B) and 4-months after (C)*Campylobacter*infection.**](1756-0500-6-391-1){#F1}

![**Mast cells in the lamina propria before*Campylobacter*infection (A) and (B) 4- months after*Campylobacter*infection.**](1756-0500-6-391-2){#F2}

###### 

**Number of colonic intraepithelial (IE) and lamina propria (LP) immune cells before, during and after*Campylobacter*infection**

  **Cell type**           **Before infection**   **During infection**   **After infection**   **Controls**^**c**^**95% confidence interval**  
  ---------------------- ---------------------- ---------------------- --------------------- ------------------------------------------------ --------
  Leucocytes in LP^a^              69                    268                    102                                199                         81-118
  Leucocytes in IE^b^             110                    224                    162                                150                         78-115
  Lymphocytes in LP^a^             3                      39                     2                                  2                           0-5
  Lymphocytes in IE^b^             1                      6                      7                                  8                           0-2
  Mast cells^a^                    7                      17                    11                                  12                          6-10

Quantifications of cells were conducted in ten randomly chosen fields using the Olympus CellSense software.

^a^Number of cells per field.

^b^Number of cells per mm^2^ of epithelium.

^c^The control group comprised 27subjects (16 females and 11 males; mean age 52 years, range 20--69 years) who had submitted to colonoscopy for the following reasons: gastrointestinal bleeding, where the source of bleeding was identified as haemorrhoids (*n*=18), or angiodysplasia (*n*=2), and health worries resulting from a relative being diagnosed with colon carcinoma (*n*=7).

###### 

**Densities of rectal IE and LP immune endocrine cells before, during and after*Campylobacter*infection**

  **Cell type**        **Before infection**   **During infection**   **After infection**   **Controls 95% confidence interval**  
  ------------------- ---------------------- ---------------------- --------------------- -------------------------------------- ---------
  Leucocytes in LP              71                    298                    104                           202                    82--112
  Leucocytes in IE             105                    224                    172                           153                    81--120
  Lymphocytes in LP             1                      42                     2                             2                       0-6
  Lymphocytes in IE             2                      7                      7                             9                       0-2
  Mast cells                    9                      19                    14                             15                     9-12

Quantifications and controls are the same as in Table [2](#T2){ref-type="table"}.

###### 

Endocrine cell densities in the colon before, during and after *Campylobacter* infection

  **Cell type**     **Before infection**   **During infection**   **After infection**   **Controls 95% confidence interval**  
  ---------------- ---------------------- ---------------------- --------------------- -------------------------------------- -------
  Chromogranin A             7                      59                    50                             20                    32-43
  Serotonin                  5                      32                    32                             28                    27-32
  PYY                        4                      29                    20                             15                    6-10

Quantifications and controls are the same as in Table [2](#T2){ref-type="table"}.

###### 

Densities of rectal endocrine cells before, during and after *Campylobacter* infection

  **Cell type**     **Before infection**   **During infection**   **After infection**   **Controls 95% confidence interval**  
  ---------------- ---------------------- ---------------------- --------------------- -------------------------------------- ----------
  Chromogranin A             35                    154                    50                             65                    108--136
  Serotonin                  21                     83                    32                             43                     32--51
  PYY                        16                     49                    24                             29                     54--67
  Somatostatin               22                     9                      3                             15                     14--20

Quantifications and controls are the same as in Table [2](#T2){ref-type="table"}.

![**Serotonin immunoreactive cells before (A), during (B) and 4 months after (C)*Campylobacter*infection.**](1756-0500-6-391-3){#F3}

Discussion
==========

Consistent with previously published observations, the present case developed a low-grad inflammation following *Campylobacter* infection \[[@B1],[@B5],[@B11],[@B16],[@B26]-[@B31]\]. An increase in the densities of intestinal endocrine cells, and especially serotonin and PYY cells, has been reported in Crohn's disease, ulcerative colitis and lymphocytic colitis \[[@B32]-[@B35]\]. An increase in the density of intestinal endocrine has also been described in PI-IBS \[[@B5],[@B11],[@B15],[@B16],[@B28],[@B30],[@B31],[@B33]\]. Several studies have shown that inflammation and immune cells affect the neuroendocrine system of the gut (the endocrine/immune axis) \[[@B1],[@B36]\]. It seems that infection/inflammation induces an increase in the population of certain gut endocrine cells through an interaction between those cells and immune cells \[[@B1],[@B36]\].

The pattern of symptoms in the present patient changed from IBS-C to IBS-M with much less abdominal pain. Serotonin activates the submucosal sensory branch of the enteric nervous system, and controls gastrointestinal motility and chloride secretion *via* inter-neurons and motor neurons \[[@B13],[@B37]-[@B42]\]. PYY delays gastric emptying, inhibits gastric and pancreatic secretion, and is a major ileal brake mediator \[[@B13],[@B43],[@B44]\]. Moreover, PYY inhibits prostaglandin (PG) E2 and vasoactive intestinal peptide (VIP), both of which stimulate intestinal secretion \[[@B13],[@B45]-[@B47]\]. Administration of PYY inhibits diarrhoea in experimental animals by reducing intestinal fluid secretion and slowing colon transit \[[@B13],[@B48]\]. Somatostatin inhibits intestinal contraction, and inhibits gut exocrine and neuroendocrine secretion \[[@B13]\]. It is therefore conceivable, that the changes in the present patient's symptoms are attributable to the reported changes in the density of the endocrine cells.

It is not uncommon for IBS patients to switch from one subtype to another over time \[[@B49]-[@B52]\]. The patient presented here switched from the IBS-C subtype to the IBS-M subtype following a bout of gastroenteritis, and it is possible that intestinal infection was the underlying cause of this switch. However, 6 months following the *Campylobacter* infection, the patient switched back from IBS-M to IBS-C. *Campylobacter jejuni* produces a range of toxins including cytolethal distending toxin (24), which first produces secretory diarrhoea in the small intestine early in the illness, after which there is invasion of the distal ileum and colon to produce an inflammatory ileocolitis, which can extend all the way to the rectum \[[@B53]\]. It has been reported that PI-IBS symptoms following *Campylobacter* infection decline with time \[[@B54]-[@B56]\]. It is conceivable, therefore, to conclude that the patient returning to her original symptoms represent a recovering form PI-IBS.

The symptoms were reduced and the quality of life improved in the patient following the treatment with prucalopride, which is a highly selective serotonin 5HT~4~ receptor agonist that has been shown to stimulate gut motility \[[@B57]\]. The patient disclosed a low density of colonic serotonin cells, which is in line with previously published observations in IBS patients \[[@B14]\]. This may explain why a serotonin agonist was effective in the treatment of the reported patient.

Conclusions
===========

Gastroenteritis due to *Campylobacter* infection in patients with IBS-C causes low-grade inflammation and changes in the densities of intestinal endocrine cells. These changes may be responsible for the change in symptom pattern and the switch from IBS-C to IBS-M that were observed in the reported patient. The patient switched back to IBS-C, 6 months following the *Campylobacter* infection, probably as a recovery from IP-IBS. Furthermore, treatment with serotonin agonist was successful in the reported patient, who disclosed reduced colonic serotonin cell density.
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